Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, has told DirectorsTalk about the appointment of Carsten Schroeder to the Company’s Board as Non-Executive Director.
Carsten has over 20 years of senior leadership experience in the medical diagnostics sector. Since 2014 he has been President of the Diagnostic Division at Grifols, S.A. where he is responsible for global commercial operations and overall strategy, including leading its growth and innovation in Transfusion Medicine and Specialty Diagnostics.
Prior to that, and before its acquisition by Grifols, Carsten was President of Novartis Diagnostics. Carsten joined Novartis Diagnostics in 2010 as Vice President of Commercial Operations for the EMEA region where he oversaw expansion into new markets. During his time at Novartis he was a member of the Vaccines & Diagnostic Division Executive Committee and served as Site Head for its Emeryville campus in California. Carsten has also held executive positions with Boston Scientific, Mallinckrodt (now Covidien) and Boehringer Ingelheim.
Mr. Schroeder holds an MBA from the European School of Management in Paris (ESCP) and a Bachelor of Arts in Economics from the University of Cologne in Germany.
Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: “I am very pleased to announce the appointment of Carsten and welcome him to the Board. His successful track record of launching new products globally will be invaluable to Oncimmune as we continue to expand across the US, Europe and into Asia.”
Commenting on his appointment, Carsten Schroeder said: “Oncimmune’s EarlyCDT(R) platform technology, which can detect cancer up to four years earlier than other methods, could transform current methods of cancer detection and save the lives of patients. The opportunity to join the Board of Oncimmune was extremely appealing and I look forward to working with Geoffrey and the team.”
